Pharmaceutical Executive-10-01-2005

Pharmaceutical Executive

There's more than one way to slice and dice a deal to understand how value is distributed. In doing so, companies may be better able to construct biopartnerships that not only capitalize on the promise offered by a compound today, but minimize them against losses if a drug doesn't succeed through the pipeline.

Pharmaceutical Executive

Academic institutions look for a strong committment from the company's senior management, favorable deal terms, market depth in a specific therapeutic area, and alignment with the partner's core strategy.

Pharmaceutical Executive

In some cases simply contemplating a potential partnership will lead a company to reconsider some of its basic business strategies. That's fine, as long as everyone is clear on one thing: The important goal isn't to make a partnership. The important goal is to advance the business.

Pharmaceutical Executive
Features

October 01, 2005

In order to make the deal work, Argos had to spend a lot of time building the relationship. Taking the time to get to know and trust one another was a key component of Kirin's due diligence process.

Pharmaceutical Executive

The backbone of the business development process is a series of decision gates with agreed upon decision criteria, and clear expectations for the appropriate levels of research and analysis for each stage in the process.

Pharmaceutical Executive

Poker has become one on the most popular attractions on television and the Internet, right up there with online auctions. And if the two were ever combined-so that players could auction off their hand early in a game, with several rounds of cards remaining to be dealt-bidders might seek advice from folks in pharmaceutical business development. Because that's what we do. When we buy or sell the rights to a compound in development, we are putting a price on a gamble.

Pharmaceutical Executive
Features

October 01, 2005

Fda-approved drugs represent a company's prospects today. Drugs in the pipeline embody the company's future. But when it comes to analyzing the value of a pharma company, the pipeline is often overlooked.

Pharmaceutical Executive

When it comes to infectious diseases, biotech start-up Idenix is on a mission: to provide patients with treatments that are more effective, more tolerable, and safer than current standards of care. Though small, the Cambridge, Massachusetts-based company is well poised to become a leader in the global antiretroviral market: It has experienced top management, a strong background in medicinal chemistry and drug discovery, and a pipeline of novel treatments for hepatitis B and C and HIV. Until a couple years ago, all Idenix lacked was a financial backer to help pay the way.